Prospective evaluation of bone density in pregnant women receiving the low molecular weight heparin enoxaparin sodium
✍ Scribed by Holly L. Casele; Steven A. Laifer
- Publisher
- John Wiley and Sons
- Year
- 2000
- Tongue
- English
- Weight
- 113 KB
- Volume
- 9
- Category
- Article
- ISSN
- 1057-0802
No coin nor oath required. For personal study only.
✦ Synopsis
Objective: To evaluate changes in bone density in women receiving enoxaparin sodium during pregnancy. Methods: Bone density in the proximal femur was serially measured in 16 women receiving enoxaparin sodium (40 mg daily) during pregnancy. Baseline measurements were taken within 2 weeks of starting therapy and then at 6 -8 weeks postpartum and 6 months postpartum. Results: Patients received enoxaparin sodium for a mean duration of 25 weeks (range, 19 -32 weeks). There was no significant change in mean bone density measurement from baseline measurements to the conclusion of therapy at 6 weeks postpartum and no patient experienced a decrease in bone mass of Ͼ10% at 6 weeks postpartum. By 6 months postpartum, there was a significant mean decrease in bone density (P ϭ 0.02) and two of the 14 patients evaluated (14%) experienced an overall bone loss of Ͼ10%.
Conclusion:
The prolonged used of enoxaparin sodium may not cause significant bone loss during pregnancy.